Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects
Open Access
- 1 July 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (5) , 722-729
- https://doi.org/10.1038/sj.bjp.0704120
Abstract
In the present study, for the first time, PDE4 subtypes were identified and semi‐quantified in both CD4 and CD8 lymphocytes from healthy and asthmatic individuals. CD4 and CD8 lymphocytes from healthy and mild asymptomatic asthmatic subjects (receiving β‐agonist therapy only) were isolated from peripheral venous blood using appropriate antibody coated paramagnetic beads. PDE4 subtypes and β‐actin were identified by digoxigenin (DIG)‐labelling reverse transcriptase‐polymerase chain reaction and semi‐quantified by DIG‐detection enzyme‐linked immunosorbance assay. In CD4 and CD8 lymphocytes PDE4A, PDE4B and PDE4D were detected, with no significant differences observed between healthy and asthmatic groups. In CD8 lymphocytes, enzyme subtype expression was lower and showed more intersubject variability. In functional studies investigating the effects of various PDE inhibitors on PHA‐induced proliferation of mononuclear cells from healthy and asthmatic subjects, CDP840 (0.03–10 μM), rolipram (0.1–10 μM) and theophylline (10 μM–1 mM) inhibited PHA‐induced proliferation of mononuclear cells from healthy and asthmatic subjects in a concentration‐dependent manner, although no significant difference was observed between the groups investigated. In additional studies, total monocyte cyclic AMP PDE activity was investigated in cells isolated from asthmatic subjects both prior to and 24 h after allergen challenge. Total monocyte cyclic AMP PDE activity remained unaffected following challenge of asthmatic subjects with either house dust mite or cat dander and was inhibited in a concentration‐dependent manner by rolipram (0.01–100 μM) both before and after allergen challenge. British Journal of Pharmacology (2001) 133, 722–729; doi:10.1038/sj.bjp.0704120Keywords
This publication has 20 references indexed in Scilit:
- A Biochemical and Functional Assessment of Monocyte Phosphodiesterase Activity in Healthy and Asthmatic SubjectsPulmonary Pharmacology & Therapeutics, 2000
- Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific PhosphodiesteraseBiochemical and Biophysical Research Communications, 1998
- Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative studyJournal of Allergy and Clinical Immunology, 1997
- Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitisBritish Journal of Pharmacology, 1995
- Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytesClinical and Experimental Allergy, 1995
- Expression and regulation of human and rat phosphodiesterase type IV isogenesFEBS Letters, 1994
- Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1993
- Phosphatidic acid stimulates the rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1993
- Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?Biochemical Pharmacology, 1992
- Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP—agonist hyporesponsivenessJournal of Allergy and Clinical Immunology, 1982